Trimodal Prehabilitation with Supervised Exercise during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41430738.
- Also identified by DOI 10.1249/MSS.0000000000003931.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pancreatic cancer (PC) is highly lethal, with surgery as the only curative option, but significant postoperative morbidity. Prehabilitation shows promise in other cancers, yet no trials have examined supervised exercise during neoadjuvant chemotherapy in PC. The primary objective was to evaluate recruitment and adherence to a trimodal prehabilitation program during neoadjuvant chemotherapy in patients with nonmetastatic PC. Secondary aims included assessing changes in physical condition, fatigue, quality of life (QoL), and some biomarkers. A prospective single-center study recruited adults diagnosed with nonmetastatic PC scheduled for chemotherapy. Inclusion criteria were ECOG- performance status 0-2 and the ability to perform the one mile walk test. The intervention involved supervised exercise, respiratory muscle training, nutritional counseling, and psychological support. Primary outcomes were recruitment (10 patients/yr) and adherence (≥70% of exercise, nutrition, or psychological sessions). Secondary outcomes included cardiorespiratory fitness (six-mine walking test, mile time walk test, estimated VO 2 peak), muscular strength (sit-to-stand test and handgrip), global QoL (EORTC QLQ-C30), fatigue (PERFORM and FACIT), and body composition (body mass index). Among 35 screened patients, 14 completed the prehabilitation program, and 12 underwent surgery (in 30 months). Ten patients were recruited in 12 months. Adherence was acceptable across all components, with physical training achieving 100% attendance. Significant improvements were observed in respiratory capacity ( P = 0.000), gait speed ( P = 0.001), estimated VO 2 peak ( P = 0.002), six-mile walking test ( P = 0.021), one-mile walk test ( P = 0.000), sit-to-stand test ( P = 0.000), body mass index ( P = 0.047), fatigue PERFORM ( P = 0.023), FACIT ( P = 0.000), and QoL ( P = 0.017). Trimodal prehabilitation during neoadjuvant chemotherapy in PC can be implemented and may be associated with clinically meaningful improvements in physical fitness, fatigue, and QoL. Multicenter randomized controlled trials are warranted to determine their impact on postoperative outcomes.
Medical subject headings
- Pancreatic Neoplasms
- Neoadjuvant Therapy
- Preoperative Exercise
- Exercise Therapy